RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Results of DECIDE: DAC HYP Superior to IFN-β-1a for RRMS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 15
OP 16
DO 10.1177/155989771429012
UL http://mdc.sagepub.com/content/14/29/15.abstract
AB This article describes the results of the phase 3, randomized, double-blind, double-dummy, active-controlled Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis trial [DECIDE; NCT01064401] establishing the superiority of the humanized monoclonal antibody, daclizumab high-yield process (DAC HYP), to interferon beta-1a (IFN-β-1a) in the treatment of relapsing-remitting multiple sclerosis (RRMS).